{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.85","upperLimit":"0.95","value":"0.91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"}],"units":"Participants"}],"description":"Second event here is defined as any relapse/progression of Hodgkin Lymphoma (HL) or a previously reported second malignant neoplasm (SMN), a new SMN, or death after a first event which can be relapse/progression of HL, SMN, biopsy-proven HL following completion of Consolidation for Slow Early Response (SER) patient, positive bilateral bone marrow biopsy following completion of Consolidation for Stage IV patient, or death. If death occurs as the 1st event, it also counts as the 2nd event.","dispersionType":"95% Confidence Interval","groups":[{"description":"All Patients","id":"OG000","title":"Group 1"}],"paramType":"NUMBER","populationDescription":"This analysis excludes n=20 patients who had protocol early terminations or deviations (n=4 Regimen I, n=12 Regimen II, and n=4 Induction only).","reportingStatus":"POSTED","timeFrame":"At 4 years from enrollment","title":"Second-event-free Survival","type":"PRIMARY","unitOfMeasure":"Probability of survival"}